By Simpson Global Media News Desk
Nigeria is taking another step towards applying artificial intelligence to a regulated professional sector, following a new collaboration between the Pharmacy Council of Nigeria (PCN) and technology company Sproxil focused on the use of agentic artificial intelligence in pharmacy practice and electronic pharmacies.
The Memorandum of Collaboration was formalised on September 29, 2026, in Kigali, Rwanda, during the Investing in Innovation Africa (i3) Access to Markets event, which was held alongside the Africa HealthTech Summit. The partnership places artificial intelligence, digital pharmacy regulation and professional oversight at the centre of a developing conversation about how technology should be deployed in Nigeria's healthcare system.
Unlike conventional software that mainly responds to commands, agentic AI is designed to perform a sequence of tasks, use information from different sources and support decisions or workflows with a degree of autonomy. In a pharmacy environment, that capability could potentially be used for activities such as information exchange, compliance monitoring, auditing and professional education.
The organisations have indicated that their collaboration will focus on practical applications rather than replacing pharmacists. Sproxil says the planned work includes an agentic information exchange for online pharmacies, AI-enabled pharmacy auditing and personalised continuing education using generative AI in African languages.
The development comes at an important point in Nigeria's digital-health evolution. The country introduced the Electronic Pharmacy Regulations 2026 earlier this year, establishing a national framework for the operation of electronic pharmacies and placing requirements around licensing, professional supervision, prescription management, medicine quality, data protection, monitoring and consumer protection.
The convergence of the new regulatory framework with the PCN-Sproxil collaboration means that the debate around artificial intelligence in Nigerian pharmacy is moving beyond experimentation and towards the question of how emerging technologies can operate inside an established regulatory system.
A technology agreement with a regulatory dimension
The PCN-Sproxil collaboration is significant because it brings together two different sides of Nigeria's technology ecosystem.
The Pharmacy Council of Nigeria is the statutory regulator responsible for controlling and regulating pharmacy education, training and practice in the country. Sproxil, meanwhile, is a technology company with experience in digital systems, real-world data and healthcare technology.
The agreement therefore does not represent a technology company independently introducing an AI product into the pharmacy market. Instead, the announced collaboration places the regulator and technology developer in the same framework as they explore possible applications of artificial intelligence.
The formal signing in Kigali was one of two partnership agreements scheduled as part of the September 29 Access to Markets programme organised by Investing in Innovation Africa. The event brought together health technology innovators, healthcare organisations, government representatives, investors, donors and other stakeholders seeking to develop commercial and institutional partnerships in African healthcare.
The official programme identified Sproxil and the Pharmacy Council of Nigeria among the organisations participating in a memorandum-signing ceremony.
Sproxil subsequently announced that the collaboration would concentrate on agentic AI systems for pharmacists and electronic pharmacies.
That announcement gives the technology agreement a broader significance than a conventional corporate partnership. It suggests an attempt to connect AI development with the practical needs of a regulated profession, where technology must operate alongside professional judgement, legal requirements and patient-safety obligations.
What agentic AI could mean for pharmacy
Artificial intelligence is already being used in healthcare for activities ranging from data analysis and medical imaging to administrative automation and decision support.
Agentic AI represents a further development in that progression.
Rather than simply generating an answer when a user asks a question, an agentic system can be designed to undertake a series of related actions according to defined instructions and permissions. It can retrieve information, compare data, identify a condition that requires attention and initiate a workflow.
In pharmacy, that distinction matters.
A digital pharmacy environment can generate large quantities of information involving prescriptions, medicines, patient interactions, professional records, regulatory requirements and transactions. The challenge is not simply collecting the information but ensuring that it can be organised and used responsibly.
An appropriately designed AI system could potentially help identify patterns, flag unusual activities, support compliance reviews or assist professionals in navigating large amounts of information.
That does not mean the technology should independently make clinical decisions.
The early description of the PCN-Sproxil collaboration instead emphasises systems intended to support pharmacists and e-pharmacies. The approach places professional practice and regulation at the centre of the proposed technology.
That distinction will be important as implementation develops.
Pharmacy is not simply another commercial sector in which automation can be judged on speed and efficiency alone. Medicines affect human health, and mistakes can have serious consequences. Any AI system operating in the sector must therefore be evaluated not only for technical performance but also for accuracy, accountability, privacy, explainability and professional oversight.
The three areas at the centre of the partnership
Sproxil's description of the collaboration identifies three major areas of potential activity.
The first is an agentic information exchange for online pharmacies.
Electronic pharmacies depend on reliable communication between different parts of the pharmaceutical ecosystem. Pharmacists, regulators, healthcare providers, patients and digital platforms may need access to different types of information at different stages of a transaction or professional process.
An intelligent information-exchange system could potentially make that process more efficient by helping authorised users retrieve and process relevant information.
The technology could also support the identification of missing or inconsistent information before a transaction or process progresses.
However, the usefulness of such a system would depend heavily on the quality and reliability of the information available to it.
AI does not automatically make poor data reliable.
If information entering a digital system is incomplete, outdated or inaccurate, an automated system can potentially reproduce or amplify those weaknesses. For that reason, the development of an agentic information exchange will require strong data standards, clear access controls and effective mechanisms for human review.
The second area is AI-enabled pharmacy auditing.
Auditing is an important part of regulation because regulators need mechanisms to determine whether regulated activities are being conducted according to established requirements.
Traditional auditing can require significant amounts of human time, particularly where large volumes of records have to be reviewed.
AI could potentially assist by identifying patterns that deserve further examination, flagging unusual transactions, checking documentation or helping regulators prioritise areas for investigation.
Such systems would not necessarily determine that a pharmacy has violated a regulation. Instead, they could help human regulators focus attention on records or activities that require closer examination.
That distinction is critical.
An AI-generated alert should be treated as an indication for human review rather than automatically becoming a regulatory finding.
The third area is continuing education for pharmacists, including personalised generative-AI support in African languages.
This part of the proposal could have a different type of impact.
Pharmacists work in an environment where professional knowledge must evolve continuously. New medicines, new regulations, new technologies and changing patterns of disease all require professionals to update their knowledge.
Generative AI could potentially help personalise learning materials, answer educational questions and make professional-development resources easier to access.
The reference to African languages is particularly relevant in a country where language diversity can influence how digital information is accessed and understood.
However, language accessibility must be matched by technical and professional accuracy. A system that communicates in a local language but produces incorrect pharmaceutical information would create a different kind of risk.
Nigeria's new electronic-pharmacy framework
The timing of the collaboration is important because Nigeria already has a new regulatory framework for electronic pharmacy practice.
The Electronic Pharmacy Regulations 2026 were launched in April following their development under the Pharmacy Council of Nigeria.
The regulations establish requirements for the registration and licensing of electronic pharmacy service providers and electronic pharmacy aggregators.
They also address prescription management, the dispensing of prescription-only medicines, patient counselling, authentication of patients, restrictions on medicines that can be purchased online and other aspects of digital pharmacy operations.
The framework also introduces the National Electronic Pharmacy Platform as a central mechanism for facilitating and monitoring electronic pharmacy services.
That regulatory structure provides the context within which new AI systems will have to operate.
The importance of this cannot be overstated.
The expansion of online pharmacy services creates opportunities for greater convenience and access, but it can also create new risks. Digital platforms can make it easier for consumers to search for and purchase medicines, yet regulators must ensure that the medicines being sold are legitimate, that prescription requirements are respected and that consumers receive appropriate professional guidance.
The Electronic Pharmacy Regulations therefore seek to establish a controlled environment in which digital pharmacy can develop.
The new AI collaboration is taking place within that environment rather than outside it.
Data protection becomes central to AI pharmacy
One of the most important issues surrounding the deployment of AI in pharmacy will be data protection.
Digital pharmacy systems can process highly sensitive information. Records may include customer identities, medicines supplied, prescriptions, consultations and other information associated with healthcare interactions.
The Electronic Pharmacy Regulations contain specific requirements concerning the handling and protection of user information and require electronic pharmaceutical service providers to comply with applicable data-protection laws.
The regulations also provide for safeguards such as secure storage, restricted access and procedures for dealing with data breaches.
This creates an important responsibility for any AI technology introduced into the sector.
The more information an AI system can access, the greater the importance of defining exactly what information it is permitted to use, who can access the information and how long that information can be retained.
An agentic system is potentially more complex than a conventional database because it may be designed to move information between different stages of a workflow.
That means security cannot be treated as an afterthought.
Authentication, access controls, audit trails, encryption and monitoring will all be important considerations.
There will also be a need to ensure that data used for AI development is obtained and processed lawfully.
Human oversight will remain critical
The introduction of agentic AI into pharmacy also raises a fundamental question: how much authority should an automated system have?
The answer will be particularly important in a sector where technology can influence decisions involving medicines and patients.
An AI system may be able to recognise patterns more quickly than a person, but speed does not eliminate the need for professional responsibility.
The PCN-Sproxil collaboration has been described as an effort to apply emerging technology responsibly, with pharmacists remaining at the centre of digital progress.
That principle will need to guide implementation.
An AI system could help a pharmacist identify relevant information, but the pharmacist should remain accountable for professional decisions within the applicable regulatory framework.
Similarly, an AI auditing tool could identify an unusual pattern, but the regulator should determine whether the pattern represents a genuine compliance problem.
This human-in-the-loop approach is likely to be particularly important during the early stages of deployment.
It would allow technology to assist professionals while providing opportunities to identify errors, biases and weaknesses in AI systems before they become widespread.
Why the partnership matters for Nigeria's technology sector
The development also demonstrates how Nigeria's technology industry is increasingly moving into specialised sectors.
Nigeria has developed a large technology ecosystem around financial services, payments, telecommunications and consumer applications.
Healthcare presents a different challenge.
Technology companies operating in health-related fields must work with regulators, professional bodies and healthcare institutions. Products cannot be designed solely around consumer demand.
The PCN-Sproxil agreement reflects that reality.
It is an example of a technology company and a regulator exploring how emerging technology can be aligned with professional standards.
For Nigeria's wider technology ecosystem, such arrangements could become increasingly important as artificial intelligence expands into areas such as education, agriculture, government services, finance, manufacturing and healthcare.
The central issue will be whether technology can be deployed in a manner that combines innovation with public trust.
From digital pharmacies to intelligent pharmacies
Electronic pharmacy is still a developing part of Nigeria's digital economy.
Consumers are increasingly accustomed to accessing services online, and healthcare is no exception.
People can already use digital channels to obtain health information, communicate with healthcare professionals and interact with pharmaceutical businesses.
The introduction of AI could make these systems more sophisticated.
Instead of simply providing a digital storefront, an online pharmacy could potentially use intelligent systems to organise information, identify missing prescription details, assist with compliance processes or provide educational resources.
But a more sophisticated system is not necessarily a better system.
The objective must remain safe and appropriate pharmaceutical practice.
Technology should not encourage people to bypass pharmacists or professional requirements simply because an automated system makes transactions faster.
The success of digital pharmacy will ultimately depend on whether consumers trust the services they use.
The question of counterfeit and unsafe medicines
Technology also has a potential role in addressing one of the longstanding challenges in pharmaceutical supply chains: medicine authenticity.
Sproxil has historically worked in areas involving medicine authentication, supply-chain information and digital health systems.
The company's wider technology experience provides a foundation for its involvement in the new AI-focused collaboration.
AI could potentially make it easier to analyse information from pharmaceutical transactions and identify unusual patterns.
For example, systems may be able to flag discrepancies that would otherwise be difficult to detect manually.
However, artificial intelligence should not be presented as a complete solution to counterfeit medicines.
The problem involves manufacturing, distribution, regulation, enforcement, consumer behaviour and supply-chain management.
Technology can provide another layer of intelligence, but it cannot replace physical verification, regulatory enforcement or responsible pharmaceutical practice.
African-language AI and professional education
The proposal to use generative AI for continuing education in African languages is another element that could attract attention beyond the pharmacy industry.
Much of the world's AI development has been driven by data and content in a relatively small number of globally dominant languages.
African countries have large populations that communicate in many languages, and the availability of useful digital tools in those languages remains uneven.
Nigeria's linguistic diversity makes the issue particularly important.
If professional education systems can use AI to adapt materials into languages that are more accessible to users, technology could help broaden participation.
But translation in a professional environment has to meet a high standard.
A small linguistic error in an ordinary conversation may cause inconvenience. A misunderstanding involving a medicine, dosage, contraindication or regulatory requirement can have far more serious consequences.
For that reason, any AI-supported professional education system will require validation by qualified experts.
Regulation must evolve alongside technology
One of the broader lessons from the PCN-Sproxil collaboration is that technology develops faster than regulatory systems can sometimes adapt.
Agentic AI is a rapidly developing field.
The capabilities of AI systems available today can be significantly different from those available only a few years ago. New models can interact with software, retrieve information, perform multi-step tasks and adapt workflows.
Regulators therefore face a continuing challenge.
Rules need to be strong enough to protect the public but flexible enough to accommodate legitimate technological development.
Nigeria's Electronic Pharmacy Regulations provide a foundation for digital pharmacy, but the emergence of increasingly sophisticated AI systems may require continuing review of how those systems are governed.
Questions around responsibility will become increasingly important.
If an AI system makes an error, who is responsible?
If an automated system incorrectly flags a pharmacy, what process exists for appeal?
If an AI system provides inaccurate educational material to a pharmacist, who validates and corrects it?
If an algorithm processes sensitive patient information, who has access to that information?
These are not theoretical questions. They are issues that will become more important as AI moves from experimentation into operational systems.
The need for measurable results
The PCN-Sproxil agreement is at an early stage.
The organisations have described the signing as the beginning of their collaboration, with additional jointly approved initiatives expected as the partnership develops.
That means it is too early to determine the ultimate impact of the technology.
The next phase will be important because it should demonstrate whether the proposed systems can move from an agreement to practical implementation.
Evidence will matter.
Stakeholders will need to know whether AI-supported auditing actually improves regulatory oversight, whether information exchange reduces administrative delays, whether professional education becomes more accessible and whether the systems improve rather than complicate pharmacy operations.
The technology will also need to demonstrate that it can operate reliably within Nigeria's regulatory environment.
A test case for responsible AI
The pharmacy collaboration can therefore be viewed as a test case for a larger question facing Nigeria's technology sector.
The country is seeking to expand its digital economy and encourage innovation, while also protecting citizens and strengthening regulatory institutions.
Artificial intelligence sits directly at the intersection of those objectives.
If Nigeria can develop AI systems that are useful, secure and accountable, the benefits could extend well beyond individual industries.
But if technology is deployed without adequate oversight, public confidence could suffer.
That is why the PCN-Sproxil agreement is notable not simply because it involves AI, but because it involves AI within a regulated profession.
The experiment will be watched closely by other sectors considering similar approaches.
What happens next
For now, the agreement provides a framework for collaboration rather than a completed national AI deployment.
The next steps are expected to involve the development and refinement of jointly approved initiatives.
The organisations will need to establish technical specifications, governance arrangements, professional safeguards and implementation procedures before any large-scale deployment can be assessed.
The PCN will retain its statutory regulatory responsibilities.
That means any technology introduced into Nigeria's pharmacy ecosystem will have to operate within the country's existing legal and professional requirements.
Sproxil, meanwhile, brings technology, data and AI capabilities to the collaboration.
The effectiveness of the partnership will depend on how successfully those capabilities can be aligned with the regulator's responsibilities.
For the Nigerian technology industry, that alignment may prove just as important as the underlying AI itself.
A new phase for Nigerian digital health
Nigeria's digital transformation is increasingly moving from basic digitisation towards systems capable of analysing information and supporting complex decisions.
The PCN-Sproxil agreement is part of that transition.
Electronic pharmacies are already changing how pharmaceutical services can be accessed. The addition of agentic AI could introduce a further layer of automation, intelligence and personalised support.
But the country's experience will also demonstrate the limits that responsible innovation must observe.
Pharmacy remains a professional service.
Patients need qualified professionals. Medicines require appropriate oversight. Sensitive information requires protection. Regulators need effective monitoring systems.
Artificial intelligence can assist with each of those functions, but it cannot remove the need for human accountability.
The immediate significance of the new collaboration is therefore not that Nigeria has suddenly entered an era of fully automated pharmacy.
Rather, it is that one of the country's key healthcare regulators and a technology company have formally begun exploring how more advanced AI can be integrated into pharmacy without abandoning professional standards.
That approach could become increasingly relevant as other Nigerian industries consider similar partnerships.
The challenge will be to ensure that the pursuit of technological sophistication remains connected to practical outcomes.
For pharmacy, those outcomes are clear: safer services, better information, stronger regulatory oversight, improved professional education and greater trust in digital channels.
If the PCN-Sproxil collaboration can demonstrate progress in those areas, it could become an important example of how Nigeria can use artificial intelligence not merely as a symbol of technological ambition, but as a practical tool within institutions that directly affect people's lives.
For now, the partnership marks the beginning of that process.
Nigeria's next step will be to turn the agreement into systems that can be tested, evaluated and, where they prove effective, responsibly scaled.
Comments
Post a Comment